Molecular mechanisms of action and therapeutic uses of pharmacological inhibitors of hif-prolyl 4-hydroxylases for treatment of ischemic diseases

Antioxidants and Redox Signaling

Volumn 20, Issue 16, 2014, Pages 2631-2665

  Selvaraju, Vaithinathan ^a   Parinandi, Narasimham L ^b   Adluri, Ram Sudheer ^a   Goldman, Joshua W ^a   Hussain, Naveed ^c,d   Sanchez, Juan A ^a   Maulik, Nilanjana ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^d Division of Emergency Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ADENOSINE A2B RECEPTOR; CARDIOVASCULAR AGENT; COLLAGEN; CYTOKINE; ERYTHROPOIETIN; FG 2216; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; GSK 360A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; N(G) METHYLARGININE; NEDD8 PROTEIN; OXYGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN KINASE B; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TM 6008; TM 6089; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; PROLYL HYDROXYLASE INHIBITOR;

ANEMIA; ANGIOGENESIS; APOPTOSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CORONARY ARTERY BYPASS GRAFT; DRUG INDUSTRY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME SPECIFICITY; ERYTHROPOIESIS; GASTROINTESTINAL DISEASE; GLYCOLYSIS; HEART PROTECTION; HUMAN; HYPOXIA; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIA; KIDNEY DISEASE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REPERFUSION INJURY; RETINOPATHY; REVIEW; STENT; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; ENZYMOLOGY; METABOLISM; MYOCARDIAL ISCHEMIA; STRUCTURE ACTIVITY RELATION;

HUMANS; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; MOLECULAR STRUCTURE; MYOCARDIAL ISCHEMIA; PROLYL-HYDROXYLASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84900443348     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5186     Document Type: Review

References (218)

1. -/-) attenuates ex vivo myocardial ischemia/reperfusion injury through hypoxia-inducible factor-1alpha transcription factor and its target genes in mice. Antioxid Redox Signal 15: 1789-1797, 2011.
2. Adluri RS, Thirunavukkarasu M, Zhan L, Akita Y, Samuel SM, Otani H, Ho YS, Maulik G, and Maulik N. Thioredoxin 1 enhances neovascularization and reduces ventricular remodeling during chronic myocardial infarction: a study using thioredoxin 1 transgenic mice. J Mol Cell Cardiol 50: 239-247, 2011.
3. Aminova LR, Siddiq A, and Ratan RR. Antioxidants, HIF prolyl hydroxylase inhibitors or short interfering RNAs to BNIP3 or PUMA, can prevent prodeath effects of the transcriptional activator, HIF-1alpha, in a mouse hippo-campal neuronal line. Antioxid Redox Signal 10: 1989-1998, 2008.
4. Anderson K, Nordquist KA, Gao X, Hicks KC, Zhai B, Gygi SP, and Patel TB. Regulation of cellular levels of Sprouty2 protein by prolyl hydroxylase domain and von Hippel-Lindau proteins. J Biol Chem 286: 42027-42036, 2011.
5. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, and Gleadle JM. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 279: 38458-38465, 2004.
6. Baek JH, Mahon PC, Oh J, Kelly B, Krishnamachary B, Pearson M, Chan DA, Giaccia AJ, and Semenza GL. OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1alpha. Mol Cell 17: 503-512, 2005.
7. Bao W, Qin P, Needle S, Erickson-Miller CL, Duffy KJ, Ariazi JL, Zhao S, Olzinski AR, Behm DJ, Pipes GT, Jucker BM, Hu E, Lepore JJ, and Willette RN. Chronic inhibition of hypoxia-inducible factor (HIF) prolyl 4-hydroxylase improves ventricular performance, remodeling and vascular-ity following myocardial infarction in the rat. J Cardiovasc Pharmacol 56: 147-155, 2010.
8. Baranova O, Miranda LF, Pichiule P, Dragatsis I, Johnson RS, and Chavez JC. Neuron-specific inactivation of the hypoxia inducible factor 1 alpha increases brain injury in a mouse model of transient focal cerebral ischemia. J Neurosci 27: 6320-6332, 2007.
9. Bell EL, Klimova TA, Eisenbart J, Moraes CT, Murphy MP, Budinger GR, and Chandel NS. The Qo site of the mito-chondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. J Cell Biol 177: 1029-1036, 2007.
10. Benard G and Rossignol R. Ultrastructure of the mitochondrion and its bearing on function and bioenergetics. Antioxid Redox Signal 10: 1313-1342, 2008.
11. Bergeron M, Gidday JM, Yu AY, Semenza GL, Ferriero DM, and Sharp FR. Role of hypoxia-inducible factor-1 in hyp-oxia-induced ischemic tolerance in neonatal rat brain. Ann Neurol 48: 285-296, 2000.
12. Bernhardt WM, Campean V, Kany S, Jurgensen JS, Weidemann A, Warnecke C, Arend M, Klaus S, Gunzler V, Amann K, Willam C, Wiesener MS, and Eckardt KU. Pre-conditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J Am Soc Nephrol 17: 1970-1978, 2006.
13. Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Gunzler V, and Eckardt KU. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 21: 2151-2156, 2010.
14. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, and Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 22: 4082-4090, 2003.
15. Bianchi G, Di Giulio C, Rapino C, Rapino M, Antonucci A, and Cataldi A. p53 and p66 proteins compete for hypoxia-inducible factor 1 alpha stabilization in young and old rat hearts exposed to intermittent hypoxia. Gerontology 52: 17-23, 2006.
16. Bishop T, Gallagher D, Pascual A, Lygate CA, de Bono JP, Nicholls LG, Ortega-Saenz P, Oster H, Wijeyekoon B, Sutherland AI, Grosfeld A, Aragones J, Schneider M, van Geyte K, Teixeira D, Diez-Juan A, Lopez-Barneo J, Chan-non KM, Maxwell PH, Pugh CW, Davies AM, Carmeliet P, and Ratcliffe PJ. Abnormal sympathoadrenal development and systemic hypotension in PHD3-/-mice. Mol Cell Biol 28: 3386-3400, 2008.
17. Bishop T, Talbot NP, Turner PJ, Nicholls LG, Pascual A, Hodson EJ, Douglas G, Fielding JW, Smith TG, Deme-triades M, Schofield CJ, Robbins PA, Pugh CW, Buckler KJ, and Ratcliffe PJ. Carotid body hyperplasia and enhanced ventilatory responses to hypoxia in mice with heterozygous deficiency of PHD2. J Physiol 591(Pt 14): 3565-3577, 2013.
18. Biswas S, Mukherjee R, Tapryal N, Singh AK, and Mukhopadhyay CK. Insulin Regulates hypoxia-inducible factor-1alpha transcription by reactive oxygen species sensitive activation of Sp1 in 3T3-L1 preadipocyte. PLoS One 8: e62128, 2013.
19. Brafman A, Mett I, Shafir M, Gottlieb H, Damari G, Gozlan-Kelner S, Vishnevskia-Dai V, Skaliter R, Einat P, Faerman A, Feinstein E, and Shoshani T. Inhibition of oxygen-induced retinopathy in RTP801-deficient mice. Invest Oph-thalmol Vis Sci 45: 3796-3805, 2004.
20. Brown ST and Nurse CA. Induction of HIF-2alpha is dependent on mitochondrial O2 consumption in an O2-sensitive adrenomedullary chromaffin cell line. Am J Physiol Cell Physiol 294: C1305-C1312, 2008.
21. Bruegge K, Jelkmann W, and Metzen E. Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases. Curr Med Chem 14: 1853-1862, 2007.
22. Bruick RK. Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor. Genes Dev 17: 2614-2623, 2003.
23. Bruick RK and McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337-1340, 2001.
24. Brunelle JK, Bell EL, Quesada NM, Vercauteren K, Tiranti V, Zeviani M, Scarpulla RC, and Chandel NS. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab 1: 409-414, 2005.
25. Bussolati B, Lauritano C, Moggio A, Collino F, Mazzone M, and Camussi G. Renal CD133+/CD73+ progenitors produce erythropoietin under hypoxia and prolyl hydroxylase inhibition. J Am Soc Nephrol 24: 1234-1241, 2013.
26. Carrero P, Okamoto K, Coumailleau P, O'Brien S, Tanaka H, and Poellinger L. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. Mol Cell Biol 20: 402-415, 2000.
27. Cervera AM, Apostolova N, Luna-Crespo F, Sanjuan-Pla A, Garcia-Bou R, and McCreath KJ. An alternatively spliced transcript of the PHD3 gene retains prolyl hydroxylase activity. Cancer Lett 233: 131-138, 2006.
28. Chen C, Hu Q, Yan J, Lei J, Qin L, Shi X, Luan L, Yang L, Wang K, Han J, Nanda A, and Zhou C. Multiple effects of 2ME2 and D609 on the cortical expression of HIF-1alpha and apoptotic genes in a middle cerebral artery occlusion-induced focal ischemia rat model. J Neurochem 102: 1831-1841, 2007.
29. Chen J, Connor KM, Aderman CM, and Smith LE. Ery-thropoietin deficiency decreases vascular stability in mice. J Clin Invest 118: 526-533, 2008.
30. Chen J, Connor KM, Aderman CM, Willett KL, Aspegren OP, and Smith LE. Suppression of retinal neovasculariza-tion by erythropoietin siRNA in a mouse model of prolif-erative retinopathy. Invest Ophthalmol Vis Sci 50: 1329-1335, 2009.
31. Chen J and Smith LE. Retinopathy of prematurity. Angio-genesis 10: 133-140, 2007.
32. Chen JX and Stinnett A. Ang-1 gene therapy inhibits hypoxia-inducible factor-1alpha (HIF-1alpha)-prolyl-4-hydroxylase-2, stabilizes HIF-1alpha expression, and normalizes immature vasculature in db/db mice. Diabetes 57: 3335-3343, 2008.
33. Chen W, Jadhav V, Tang J, and Zhang JH. HIF-1alpha inhibition ameliorates neonatal brain injury in a rat pup hypoxic-ischemic model. Neurobiol Dis 31: 433-441, 2008.
34. Chowdhury R, Godoy LC, Thiantanawat A, Trudel LJ, Deen WM, and Wogan GN. Nitric oxide produced en-dogenously is responsible for hypoxia-induced HIF-1alpha stabilization in colon carcinoma cells. Chem Res Toxicol 25: 2194-2202, 2012.
35. Chua YL, Dufour E, Dassa EP, Rustin P, Jacobs HT, Taylor CT, and Hagen T. Stabilization of hypoxia-inducible factor-1alpha protein in hypoxia occurs independently of mito-chondrial reactive oxygen species production. J Biol Chem 285: 31277-31284, 2010.
36. Chung LC, Tsui KH, Feng TH, Lee SL, Chang PL, and Juang HH. Curcumin provides potential protection against the activation of hypoxia and prolyl 4-hydroxylase inhibitors on prostate-specific antigen expression in human prostate carcinoma cells. Mol Nutr Food Res 55: 1666-1676, 2011.
37. Colla S, Tagliaferri S, Morandi F, Lunghi P, Donofrio G, Martorana D, Mancini C, Lazzaretti M, Mazzera L, Ravanetti L, Bonomini S, Ferrari L, Miranda C, Ladetto M, Neri TM, Neri A, Greco A, Mangoni M, Bonati A, Rizzoli V, and Giuliani N. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood 110: 4464-4475, 2007.
38. Conway EM, Collen D, and Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res 49: 507-521, 2001.
39. Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT, Seeballuck F, Godson C, Nielsen JE, Moynagh P, Pouyssegur J, and Taylor CT. Prolyl hydrox-ylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci U S A 103: 18154-18159, 2006.
40. Cummins EP, Seeballuck F, Keely SJ, Mangan NE, Callanan JJ, Fallon PG, and Taylor CT. The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology 134: 156-165, 2008.
41. Dagogo-Jack S and Alberti KGMM. Management of diabetes mellitus in surgical patients. Diabetes Spectr 15: 44-48, 2002.
42. Dai Y, Xu M, Wang Y, Pasha Z, Li T, and Ashraf M. HIF-1alpha induced-VEGF overexpression in bone marrow stem cells protects cardiomyocytes against ischemia. J Mol Cell Cardiol 42: 1036-1044, 2007.
43. Dao JH, Kurzeja RJ, Morachis JM, Veith H, Lewis J, Yu V, Tegley CM, and Tagari P. Kinetic characterization and identification of a novel inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 using a time-resolved fluorescence resonance energy transfer-based assay technology. Anal Biochem 384: 213-223, 2009.
44. De Domenico I, McVey Ward D, and Kaplan J. Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat Rev Mol Cell Biol 9: 72-81, 2008.
45. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8: 705-713, 2008.
46. Denny WA. Giving anemia a boost with inhibitors of prolyl hydroxylase. J Med Chem 55: 2943-2944, 2012.
47. Dioum EM, Clarke SL, Ding K, Repa JJ, and Garcia JA. HIF-2alpha- haploinsufficient mice have blunted retinal neo-vascularization due to impaired expression of a proangio-genic gene battery. Invest Ophthalmol Vis Sci 49: 2714-2720, 2008.
48. Doege K, Heine S, Jensen I, Jelkmann W, and Metzen E. Inhibition of mitochondrial respiration elevates oxygen concentration but leaves regulation of hypoxia-inducible factor (HIF) intact. Blood 106: 2311-2317, 2005.
49. Duan LJ, Takeda K, and Fong GH. Prolyl hydroxylase domain protein 2 (PHD2) mediates oxygen-induced reti-nopathy in neonatal mice. Am J Pathol 178: 1881-1890, 2011.
50. Eckle T, Kohler D, Lehmann R, El Kasmi K, and Eltzschig HK. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 118: 166-175, 2008.
51. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, and Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54, 2001.
52. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 228: 1-14, 2003.
53. Flashman E, McDonough MA, and Schofield CJ. OS-9: another piece in the HIF complex story. Mol Cell 17: 472-473, 2005.
54. Floyd ZE, Kilroy G, Wu X, and Gimble JM. Effects of prolyl hydroxylase inhibitors on adipogenesis and hypoxia in-ducible factor 1 alpha levels under normoxic conditions. J Cell Biochem 101: 1545-1557, 2007.
55. Fraisl P, Aragones J, and Carmeliet P. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov 8: 139-152, 2009.
56. Freeman RS, Hasbani DM, Lipscomb EA, Straub JA, and Xie L. SM-20, EGL-9, and the EGLN family of hypoxia-inducible factor prolyl hydroxylases. Mol Cells 16: 1-12, 2003.
57. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, and Se-menza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277: 38205-38211, 2002.
58. Gong Y and Agani FH. Oligomycin inhibits HIF-1alpha expression in hypoxic tumor cells. Am J Physiol Cell Physiol 288: C1023-C1029, 2005.
59. Gordeuk VR, Miasnikova GY, Sergueeva AI, Niu X, Nouraie M, Okhotin DJ, Polyakova LA, Ammosova T, Nekhai S, Ganz T, and Prchal JT. Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression. Blood 118: 5278-5282, 2011.
60. Gruber M, Hu CJ, Johnson RS, Brown EJ, Keith B, and Simon MC. Acute postnatal ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci U S A 104: 2301-2306, 2007.
61. Guo K, Searfoss G, Krolikowski D, Pagnoni M, Franks C, Clark K, Yu KT, Jaye M, and Ivashchenko Y. Hypoxia induces the expression of the pro-apoptotic gene BNIP3. Cell Death Differ 8: 367-376, 2001.
62. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U, and Schumacker PT. Mi-tochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 1: 401-408, 2005.
63. Hagen T. Oxygen versus reactive oxygen in the regulation of HIF-1alpha: the balance tips. Biochem Res Int 2012: 436981, 2012.
64. Hagen T, Taylor CT, Lam F, and Moncada S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science 302: 1975-1978, 2003.
65. Hahn JY, Cho HJ, Bae JW, Yuk HS, Kim KI, Park KW, Koo BK, Chae IH, Shin CS, Oh BH, Choi YS, Park YB, and Kim HS. Beta-catenin overexpression reduces myocardial infarct size through differential effects on cardiomyocytes and cardiac fibroblasts. J Biol Chem 281: 30979-30989, 2006.
66. Hall MA, King NM, Perdue LH, Hilner JE, Akolkar B, Greenbaum CJ, and McKeon C. Biobanking, consent, and commercialization in international genetics research: the Type 1 Diabetes Genetics Consortium. Clin Trials 7: S33-S45, 2010.
67. Hanson ES, Rawlins ML, and Leibold EA. Oxygen and iron regulation of iron regulatory protein 2. J Biol Chem 278: 40337-40342, 2003.
68. Harten SK, Ashcroft M, and Maxwell PH. Prolyl hydrox-ylase domain inhibitors: a route to HIF activation and neuroprotection. Antioxid Redox Signal 12: 459-480, 2010.
69. He T, Ai M, Zhao XH, and Xing YQ. Inducible nitric oxide synthase mediates hypoxia-induced hypoxia-inducible factor-1 alpha activation and vascular endothelial growth factor expression in oxygen-induced retinopathy. Patho-biology 74: 336-343, 2007.
70. Heesch CM. Reflexes that control cardiovascular function. Am J Physiol 277: S234-S243, 1999.
71. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, and Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat Rep 57: 1-134, 2009.
72. Hess ML and Manson NH. Molecular oxygen: friend and foe. The role of the oxygen free radical system in the calcium paradox, the oxygen paradox and ischemia/reperfusion injury. J Mol Cell Cardiol 16: 969-985, 1984.
73. Hill P, Shukla D, Tran MG, Aragones J, Cook HT, Carmeliet P, and Maxwell PH. Inhibition of hypoxia in-ducible factor hydroxylases protects against renal ischemia-reperfusion injury. J Am Soc Nephrol 19: 39-46, 2008.
74. Hirsila M, Koivunen P, Gunzler V, Kivirikko KI, and Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem 278: 30772-30780, 2003.
75. Hirsila M, Koivunen P, Xu L, Seeley T, Kivirikko KI, and Myllyharju J. Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEB J 19: 1308-1310, 2005.
76. Hopfer U, Hopfer H, Jablonski K, Stahl RA, and Wolf G. The novel WD-repeat protein Morg1 acts as a molecular scaffold for hypoxia-inducible factor prolyl hydroxylase 3 (PHD3). J Biol Chem 281: 8645-8655, 2006.
77. Hsieh MM, Linde NS, Wynter A, Metzger M, Wong C, Langsetmo I, Lin A, Smith R, Rodgers GP, Donahue RE, Klaus SJ, and Tisdale JF. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, ery-throcytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 110: 2140-2147, 2007.
78. Huang H, Van de Veire S, Dalal M, Parlier R, Semba RD, Carmeliet P, and Vinores SA. Reduced retinal neovascu-larization, vascular permeability, and apoptosis in ischemic retinopathy in the absence of prolyl hydroxylase-1 due to the prevention of hyperoxia-induced vascular obliteration. Invest Ophthalmol Vis Sci 52: 7565-7573, 2011.
79. Huang LE, Arany Z, Livingston DM, and Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271: 32253-32259, 1996.
80. Huang M, Chan DA, Jia F, Xie X, Li Z, Hoyt G, Robbins RC, Chen X, Giaccia AJ, and Wu JC. Short hairpin RNA interference therapy for ischemic heart disease. Circulation 118: S226-S233, 2008.
81. Hyvarinen J, Hassinen IE, Sormunen R, Maki JM, Kivirikko KI, Koivunen P, and Myllyharju J. Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury. J Biol Chem 285: 13646-13657, 2010.
82. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, and Kaelin WG, Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468, 2001.
83. Jaakkola PM and Rantanen K. The regulation, localization, and functions of oxygen-sensing prolyl hydroxylase PHD3. Biol Chem 394: 449-457, 2013.
84. Jayachandran KS, Khan M, Selvendiran K, Devaraj SN, and Kuppusamy P. Crataegus oxycantha extract attenuates apoptotic incidence in myocardial ischemia-reperfusion injury by regulating Akt and HIF-1 signaling pathways. J Cardiovasc Pharmacol 56: 526-531, 2010.
85. Jiang BH, Semenza GL, Bauer C, and Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 271: C1172-C1180, 1996.
86. Jiang J, Xia XB, Xu HZ, Xiong Y, Song WT, Xiong SQ, and Li Y. Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1alpha and VEGF. J Cell Physiol 218: 66-74, 2009.
87. Kaelin WG, Jr. and Ratcliffe PJ. Oxygen sensing by meta-zoans: the central role of the HIF hydroxylase pathway. Mol Cell 30: 393-402, 2008.
88. Thirunavukkarasu M, Han Z, Zhan L, Penumathsa SV, Menon VP, and Maulik N. Adeno-sh-beta-catenin abolishes ischemic preconditioning-mediated cardioprotection by downregulation of its target genes VEGF, Bcl-2 and survi-vin in ischemic rat myocardium. Antioxid Redox Signal 10: 1475-1484, 2008.
89. Kasiganesan H, Sridharan V, and Wright G. Prolyl hy-droxylase inhibitor treatment confers whole-animal hyp-oxia tolerance. Acta Physiol (Oxf) 190: 163-169, 2007.
90. Katschinski DM. In vivo functions of the prolyl-4-hydrox-ylase domain oxygen sensors: direct route to the treatment of anaemia and the protection of ischaemic tissues. Acta Physiol (Oxf) 195: 407-414, 2009.
91. Ke Q and Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 70: 1469-1480, 2006.
92. Kho YH, Pool MO, Jansman FG, and Harting JW. Phar-macotherapeutic options in inflammatory bowel disease: an update. Pharm World Sci 23: 17-21, 2001.
93. Kilian EG, Sadoni S, Vicol C, Kelly R, van Hulst K, Schwaiger M, Kupatt C, Boekstegers P, Pillai R, Channon K, Hetzer R, and Reichart B. Myocardial transfection of hypoxia inducible factor-1alpha via an adenoviral vector during coronary artery bypass grafting-a multicenter phase I and safety study. Circ J 74: 916-924, 2010.
94. Kim JH, Yu YS, Shin JY, Lee HY, and Kim KW. Deguelin inhibits retinal neovascularization by down-regulation of HIF-1alpha in oxygen-induced retinopathy. J Cell Mol Med 12: 2407-2415, 2008.
95. Kim JW, Tchernyshyov I, Semenza GL, and Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3: 177-185, 2006.
96. Kiss J, Kirchberg J, and Schneider M. Molecular oxygen sensing: implications for visceral surgery. Langenbecks Arch Surg 397: 603-610, 2012.
97. Kiss J, Mollenhauer M, Walmsley SR, Kirchberg J, Rad-hakrishnan P, Niemietz T, Dudda J, Steinert G, Whyte MK, Carmeliet P, Mazzone M, Weitz J, and Schneider M. Loss of the oxygen sensor PHD3 enhances the innate immune response to abdominal sepsis. J Immunol 189: 1955-1965, 2012.
98. Kivirikko KI and Myllyharju J. Prolyl 4-hydroxylases and their protein disulfide isomerase subunit. Matrix Biol 16: 357-368, 1998.
99. Kivirikko KI and Pihlajaniemi T. Collagen hydroxylases and the protein disulfide isomerase subunit of prolyl 4-hydroxylases. Adv Enzymol Relat Areas Mol Biol 72: 325-398, 1998.
100. Klotzsche-von Ameln A, Muschter A, Heimesaat MM, Breier G, and Wielockx B. HIF prolyl hydroxylase-2 inhibition diminishes tumor growth through matrix metallo-proteinase-induced TGFbeta activation. Cancer Biol Ther 13: 216-223, 2012.
101. Koditz J, Nesper J, Wottawa M, Stiehl DP, Camenisch G, Franke C, Myllyharju J, Wenger RH, and Katschinski DM. Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor. Blood 110: 3610-3617, 2007.
102. Koivunen P, Tiainen P, Hyvarinen J, Williams KE, Sormu-nen R, Klaus SJ, Kivirikko KI, and Myllyharju J. An endo-plasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor alpha. J Biol Chem 282: 30544-30552, 2007.
103. Kozako T, Matsumoto N, Kuramoto Y, Sakata A, Moto-nagare R, Aikawa A, Imoto M, Toda A, Honda S, Shimeno H, and Soeda S. Vasohibin induces prolyl hydroxylase-mediated degradation of hypoxia-inducible factor-1alpha in human umbilical vein endothelial cells. FEBS Lett 586: 1067-1072, 2012.
104. Kuznetsova AV, Meller J, Schnell PO, Nash JA, Ignacak ML, Sanchez Y, Conaway JW, Conaway RC, and Czyzyk-Krzeska MF. von Hippel-Lindau protein binds hyperpho-sphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitina-tion. Proc Natl Acad Sci U S A 100: 2706-2711, 2003.
105. Li B, Takeda K, Yokoyama S, and Shibahara S. A prolyl-hydroxylase inhibitor, ethyl-3, 4-dihydroxybenzoate, induces haem oxygenase-1 expression in human cells through a mechanism independent of hypoxia-inducible factor-1alpha. J Biochem 144: 643-654, 2008.
106. Liao SH, Zhao XY, Han YH, Zhang J, Wang LS, Xia L, Zhao KW, Zheng Y, Guo M, and Chen GQ. Proteomics-based identification of two novel direct targets of hypoxia-inducible factor-1 and their potential roles in migration/invasion of cancer cells. Proteomics 9: 3901-3912, 2009.
107. Lieb ME, Menzies K, Moschella MC, Ni R, and Taubman MB. Mammalian EGLN genes have distinct patterns of mRNA expression and regulation. Biochem Cell Biol 80: 421-426, 2002.
108. Liu XB, Wang JA, Ogle ME, and Wei L. Prolyl hydroxylase inhibitor dimethyloxalylglycine enhances mesenchymal stem cell survival. J Cell Biochem 106: 903-911, 2009.
109. Loenarz C and Schofield CJ. Physiological and biochemical aspects of hydroxylations and demethylations catalyzed by human 2-oxoglutarate oxygenases. Trends Biochem Sci 36: 7-18, 2011.
110. Lomb DJ, Desouza LA, Franklin JL, and Freeman RS. Prolyl hydroxylase inhibitors depend on extracellular glucose and hypoxia-inducible factor (HIF)-2alpha to inhibit cell death caused by nerve growth factor (NGF) deprivation: evidence that HIF-2alpha has a role in NGF-promoted survival of sympathetic neurons. Mol Pharmacol 75: 1198-1209, 2009.
111. Lomb DJ, Straub JA, and Freeman RS. Prolyl hydroxylase inhibitors delay neuronal cell death caused by trophic factor deprivation. J Neurochem 103: 1897-1906, 2007.
112. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, Cole RN, Pandey A, and Semenza GL. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145: 732-744, 2011.
113. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, and Giannakakou P. 2ME2 inhibits tumor growth and angio-genesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3: 363-375, 2003.
114. Macheda ML, Rogers S, and Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202: 654-662, 2005.
115. Manalo DJ, Buehler PW, Baek JH, Butt O, D'Agnillo F, and Alayash AI. Acellular haemoglobin attenuates hypoxia-inducible factor-1alpha (HIF-1alpha) and its target genes in haemodiluted rats. Biochem J 414: 461-469, 2008.
116. Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, Garcia JG, and Semenza GL. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105: 659-669, 2005.
117. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ, and Maxwell PH. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1: 459-468, 2002.
118. Mansfield KD, Guzy RD, Pan Y, Young RM, Cash TP, Schumacker PT, and Simon MC. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab 1: 393-399, 2005.
119. Masson N, Singleton RS, Sekirnik R, Trudgian DC, Ambrose LJ, Miranda MX, Tian YM, Kessler BM, Schofield CJ, and Ratcliffe PJ. The FIH hydroxylase is a cellular peroxide sensor that modulates HIF transcriptional activity. EMBO Rep 13: 251-257, 2012.
120. Masson N, Willam C, Maxwell PH, Pugh CW, and Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 20: 5197-5206, 2001.
121. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, and Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent prote-olysis. Nature 399: 271-275, 1999.
122. Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, Hara S, Conaway RC, Conaway JW, and Ohh M. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem 278: 11032-11040, 2003.
123. Mecinovic J, Loenarz C, Chowdhury R, and Schofield CJ. 2-Oxoglutarate analogue inhibitors of prolyl hydroxylase domain 2. Bioorg Med Chem Lett 19: 6192-6195, 2009.
124. Metzen E, Berchner-Pfannschmidt U, Stengel P, Marxsen JH, Stolze I, Klinger M, Huang WQ, Wotzlaw C, Hellwig-Burgel T, Jelkmann W, Acker H, and Fandrey J. In-tracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing. J Cell Sci 116: 1319-1326, 2003.
125. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, and Ullrich A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72: 835-846, 1993.
126. Miyata T, Suzuki N, and van Ypersele de Strihou C. Diabetic nephropathy: are there new and potentially promising therapies targeting oxygen biology? Kidney Int 2013 [Epub ahead of print]; DOI: 10.1038/ki.2013.74.
127. Mollenhauer M, Kiss J, Dudda J, Kirchberg J, Rahbari N, Radhakrishnan P, Niemietz T, Rausch V, Weitz J, and Schneider M. Deficiency of the oxygen sensor PHD1 augments liver regeneration after partial hepatectomy. Lan-genbecks Arch Surg 397: 1313-1322, 2012.
128. Myllyharju J. Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. Matrix Biol 22: 15-24, 2003.
129. Myllyharju J. Prolyl 4-hydroxylases, key enzymes in the synthesis of collagens and regulation of the response to hypoxia, and their roles as treatment targets. Ann Med 40: 402-417, 2008.
130. Nagel S, Talbot NP, Mecinovic J, Smith TG, Buchan AM, and Schofield CJ. Therapeutic manipulation of the HIF hydroxylases. Antioxid Redox Signal 12: 481-501, 2010.
131. Nagy MA. HIF-1 is the commander of gateways to cancer. J Cancer Sci Ther 3: 035-040, 2011.
132. Nakayama K, Gazdoiu S, Abraham R, Pan ZQ, and Ronai Z. Hypoxia-induced assembly of prolyl hydroxylase PHD3 into complexes: implications for its activity and susceptibility for degradation by the E3 ligase Siah2. Biochem J 401: 217-226, 2007.
133. Nangaku M, Izuhara Y, Takizawa S, Yamashita T, Fujii-Kuriyama Y, Ohneda O, Yamamoto M, van Ypersele de Strihou C, Hirayama N, and Miyata T. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vasc Biol 27: 2548-2554, 2007.
134. Naranjo-Suarez S, Carlson BA, Tsuji PA, Yoo MH, Glady-shev VN, and Hatfield DL. HIF-independent regulation of thioredoxin reductase 1 contributes to the high levels of reactive oxygen species induced by hypoxia. PLoS One 7: e30470, 2012.
135. Natarajan R, Salloum FN, Fisher BJ, Kukreja RC, and Fowler AA, 3rd. Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myo-cardial ischemia reperfusion injury. Circ Res 98: 133-140, 2006.
136. Natarajan R, Salloum FN, Fisher BJ, Ownby ED, Kukreja RC, and Fowler AA, 3rd. Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium. Am J Physiol Heart Circ Physiol 293: H1571-H1580, 2007.
137. Nguyen A, Hoang V, Laquer V, and Kelly KM. Angio-genesis in cutaneous disease: part I. J Am Acad Dermatol 61: 921-942; quiz 943-944, 2009.
138. Nicholas SA and Sumbayev VV. The role of redox-depen-dent mechanisms in the downregulation of ligand-induced Toll-like receptors 7, 8 and 4-mediated HIF-1 alpha prolyl hydroxylation. Immunol Cell Biol 88: 180-186, 2010.
139. Niv Y. Capsule endoscopy in the diagnosis of Crohn's disease. Med Devices (Auckl) 6: 85-89, 2013.
140. Ockaili R, Natarajan R, Salloum F, Fisher BJ, Jones D, Fowler AA, 3rd, and Kukreja RC. HIF-1 activation attenuates postischemic myocardial injury: role for heme oxyge-nase-1 in modulating microvascular chemokine generation. Am J Physiol Heart Circ Physiol 289: H542-H548, 2005.
141. Oehme F, Ellinghaus P, Kolkhof P, Smith TJ, Ramakrishnan S, Hutter J, Schramm M, and Flamme I. Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors. Biochem Biophys Res Commun 296: 343-349, 2002.
142. Ogle ME, Gu X, Espinera AR, and Wei L. Inhibition of prolyl hydroxylases by dimethyloxaloylglycine after stroke reduces ischemic brain injury and requires hypoxia induc-ible factor-1alpha. Neurobiol Dis 45: 733-742, 2012.
143. Ohtomo S, Nangaku M, Izuhara Y, Takizawa S, Strihou CY, and Miyata T. Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model. Nephrol Dial Transplant 23: 1166-1172, 2008.
144. Oriowo B, Thirunavukkarasu M, Selvaraju V, Adluri RS, Zhan L, Takeda K, Fong GH, Sanchez JA, and Maulik N. Prolyl hydroxylase domain protein 3 silencing stabilizes hypoxia inducible factor-1 alpha and preserves myocardial function through activation of pro-angiogenic and anti-apoptotic pathway following myocardial injury in mice. Curr Pharm Des 2013 (in press).
145. Ozer A, Wu LC, and Bruick RK. The candidate tumor suppressor ING4 represses activation of the hypoxia in-ducible factor (HIF). Proc Natl Acad Sci U S A 102: 7481-7486, 2005.
146. Paltoglou S and Roberts BJ. HIF-1alpha and EPAS ubiqui-tination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases. Oncogene 26: 604-609, 2007.
147. Papetti M and Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 282: C947-C970, 2002.
148. Park AM, Sanders TA, and Maltepe E. Hypoxia-inducible factor (HIF) and HIF-stabilizing agents in neonatal care. Semin Fetal Neonatal Med 15: 196-202, 2010.
149. Petrangolini G, Pratesi G, De Cesare M, Supino R, Pisano C, Marcellini M, Giordano V, Laccabue D, Lanzi C, and Zu-nino F. Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts. Mol Cancer Res 1: 863-870, 2003.
150. Peyssonnaux C, Nizet V, and Johnson RS. Role of the hypoxia inducible factors HIF in iron metabolism. Cell Cycle 7: 28-32, 2008.
151. Philipp S, Jurgensen JS, Fielitz J, Bernhardt WM, Weidemann A, Schiche A, Pilz B, Dietz R, Regitz-Zagrosek V, Eckardt KU, and Willenbrock R. Stabilization of hypoxia inducible factor rather than modulation of collagen metabolism improves cardiac function after acute myocardial infarction in rats. Eur J Heart Fail 8: 347-354, 2006.
152. Prabhakar NR and Kumar GK. Mechanisms of sympathetic activation and blood pressure elevation by intermittent hypoxia. Respir Physiol Neurobiol 174: 156-161, 2010.
153. Prass K, Ruscher K, Karsch M, Isaev N, Megow D, Priller J, Scharff A, Dirnagl U, and Meisel A. Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro. J Cereb Blood Flow Metab 22: 520-525, 2002.
154. Rankin EB, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS, Simon MC, Keith B, and Haase VH. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest 117: 1068-1077, 2007.
155. Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Hewitt SM, Shoemaker RH, and Melillo G. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64: 6845-6848, 2004.
156. Resar JR, Roguin A, Voner J, Nasir K, Hennebry TA, Miller JM, Ingersoll R, Kasch LM, and Semenza GL. Hypoxia-inducible factor 1alpha polymorphism and coronary collaterals in patients with ischemic heart disease. Chest 128: 787-791, 2005.
157. Riby JE, Firestone GL, and Bjeldanes LF. 3, 3¢-diindo-lylmethane reduces levels of HIF-1alpha and HIF-1 activity in hypoxic cultured human cancer cells. Biochem Pharmacol 75: 1858-1867, 2008.
158. Robinson A, Keely S, Karhausen J, Gerich ME, Furuta GT, and Colgan SP. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 134: 145-155, 2008.
159. Roda JM, Wang Y, Sumner LA, Phillips GS, Marsh CB, and Eubank TD. Stabilization of HIF-2alpha induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model. J Immunol 189: 3168-3177, 2012.
160. Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, De-luca JK, Schwartz L, Bacik J, and Motzer RJ. A phase II trial of 17-(Allylamino)-17- demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 24: 543-546, 2006.
161. Rosenberger C, Mandriota S, Jurgensen JS, Wiesener MS, Horstrup JH, Frei U, Ratcliffe PJ, Maxwell PH, Bachmann S, and Eckardt KU. Expression of hypoxia-inducible factor-1alpha and-2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 13: 1721-1732, 2002.
162. Rosenberger C, Rosen S, Shina A, Frei U, Eckardt KU, Flippin LA, Arend M, Klaus SJ, and Heyman SN. Activation of hypoxia-inducible factors ameliorates hypoxic distal tubular injury in the isolated perfused rat kidney. Nephrol Dial Transplant 23: 3472-3478, 2008.
163. Rozen-Zvi B, Hayashida T, Hubchak SC, Hanna C, Platanias LC, and Schnaper HW. TGF-beta/Smad3 activates mammalian target of rapamycin complex-1 and promotes collagen production by increasing HIF-1alpha expression. Am J Physiol Renal Physiol 305: F485-F494, 2013.
164. Ryu JH, Li SH, Park HS, Park JW, Lee B, and Chun YS. Hypoxia-inducible factor alpha subunit stabilization by NEDD8 conjugation is reactive oxygen species-dependent. J Biol Chem 286: 6963-6970, 2011.
165. Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol 42: 16-25, 2007.
166. Sarkar K, Fox-Talbot K, Steenbergen C, Bosch-Marce M, and Semenza GL. Adenoviral transfer of HIF-1alpha enhances vascular responses to critical limb ischemia in diabetic mice. Proc Natl Acad Sci U S A 106: 18769-18774, 2009.
167. Schlisio S. Neuronal apoptosis by prolyl hydroxylation: implication in nervous system tumours and the Warburg conundrum. J Cell Mol Med 13: 4104-4112, 2009.
168. Schofield CJ and Zhang Z. Structural and mechanistic studies on 2-oxoglutarate-dependent oxygenases and related enzymes. Curr Opin Struct Biol 9: 722-731, 1999.
169. Sears JE, Hoppe G, Ebrahem Q, and Anand-Apte B. Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy. Proc Natl Acad Sci U S A 105: 19898-19903, 2008.
170. Semenza GL. HIF-1: mediator of physiological and patho-physiological responses to hypoxia. J Appl Physiol 88: 1474-1480, 2000.
171. Semenza GL. Hypoxia-inducible factor 1: oxygen homeo-stasis and disease pathophysiology. Trends Mol Med 7: 345-350, 2001.
172. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
173. Semenza GL. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood 114: 2015-2019, 2009.
174. Semenza GL. Regulation of oxygen homeostasis by hyp-oxia-inducible factor 1. Physiology (Bethesda) 24: 97-106, 2009.
175. Semenza GL. Regulation of vascularization by hypoxia-inducible factor 1. Ann N Y Acad Sci 1177: 2-8, 2009.
176. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 148: 399-408, 2012.
177. Shay JE and Celeste SM. Hypoxia-inducible factors: crosstalk between inflammation and metabolism. Semin Cell Dev Biol 23: 389-394, 2012.
178. Shen X, Wan C, Ramaswamy G, Mavalli M, Wang Y, Duvall CL, Deng LF, Guldberg RE, Eberhart A, Clemens TL, and Gilbert SR. Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice. J Orthop Res 27: 1298-1305, 2009.
179. Shoshani T, Faerman A, Mett I, Zelin E, Tenne T, Gorodin S, Moshel Y, Elbaz S, Budanov A, Chajut A, Kalinski H, Kamer I, Rozen A, Mor O, Keshet E, Leshkowitz D, Einat P, Skaliter R, and Feinstein E. Identification of a novel hyp-oxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol 22: 2283-2293, 2002.
180. Siddiq A, Aminova LR, and Ratan RR. Hypoxia inducible factor prolyl 4-hydroxylase enzymes: center stage in the battle against hypoxia, metabolic compromise and oxida-tive stress. Neurochem Res 32: 931-946, 2007.
181. Siddiq A, Aminova LR, Troy CM, Suh K, Messer Z, Semenza GL, and Ratan RR. Selective inhibition of hyp-oxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF-and CREB-independent pathways. J Neurosci 29: 8828-8838, 2009.
182. Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, LaManna JC, Patton SM, Connor JR, Cherny RA, Volitakis I, Bush AI, Langsetmo I, Seeley T, Gunzler V, and Ratan RR. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem 280: 41732-41743, 2005.
183. Simon MC. Coming up for air: HIF-1 and mitochondrial oxygen consumption. Cell Metab 3: 150-151, 2006.
184. Song X, Yao J, Wang F, Zhou M, Zhou Y, Wang H, Wei L, Zhao L, Li Z, Lu N, and Guo Q. Wogonin inhibits tumor angiogenesis via degradation of HIF-1alpha protein. Toxicol Appl Pharmacol 271: 144-155, 2013.
185. Stiehl DP, Wirthner R, Koditz J, Spielmann P, Camenisch G, and Wenger RH. Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an autoregulatory oxygen-sensing system. J Biol Chem 281: 23482-23491, 2006.
186. Takaku M, Tomita S, Kurobe H, Kihira Y, Morimoto A, Higashida M, Ikeda Y, Ushiyama A, Hashimoto I, Naka-nishi H, and Tamaki T. Systemic preconditioning by a prolyl hydroxylase inhibitor promotes prevention of skin flap necrosis via HIF-1-induced bone marrow-derived cells. PLoS One 7: e42964, 2012.
187. Takeda K, Aguila HL, Parikh NS, Li X, Lamothe K, Duan LJ, Takeda H, Lee FS, and Fong GH. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood 111: 3229-3235, 2008.
188. Takeda K, Cowan A, and Fong GH. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation 116: 774-781, 2007.
189. Tambuwala MM, Cummins EP, Lenihan CR, Kiss J, Stauch M, Scholz CC, Fraisl P, Lasitschka F, Mollenhauer M, Saunders SP, Maxwell PH, Carmeliet P, Fallon PG, Schneider M, and Taylor CT. Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell ap-optosis and increased barrier function. Gastroenterology 139: 2093-2101, 2010.
190. Tanaka T, Kojima I, Ohse T, Ingelfinger JR, Adler S, Fujita T, and Nangaku M. Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. Lab Invest 85: 1292-1307, 2005.
191. Tanaka T and Nangaku M. Drug discovery for overcoming chronic kidney disease (CKD): prolyl-hydroxylase inhibitors to activate hypoxia-inducible factor (HIF) as a novel therapeutic approach in CKD. J Pharmacol Sci 109: 24-31, 2009.
192. Teli MK and Krishnamurthy RG. A combination of 3D-QSAR modeling and molecular docking approach for the discovery of potential HIF prolyl hydroxylase inhibitors. Med Chem 9: 360-370, 2013.
193. Teli MK and Rajanikant GK. Identification of novel potential HIF-prolyl hydroxylase inhibitors by in silico screening. Mol Divers 16: 193-202, 2012.
194. Teng Y, Cui H, Yang M, Song H, Zhang Q, Su Y, and Zheng J. Protective effect of puerarin on diabetic retinop-athy in rats. Mol Biol Rep 36: 1129-1133, 2009.
195. Thangarajah H, Vial IN, Grogan RH, Yao D, Shi Y, Ja-nuszyk M, Galiano RD, Chang EI, Galvez MG, Glotzbach JP, Wong VW, Brownlee M, and Gurtner GC. HIF-1alpha dysfunction in diabetes. Cell Cycle 9: 75-79, 2010.
196. Thirstrup K, Christensen S, Moller HA, Ritzen A, Bergstrom AL, Sager TN, and Jensen HS. Endogenous 2-oxoglutarate levels impact potencies of competitive HIF prolyl hydroxylase inhibitors. Pharmacol Res 64: 268-273, 2011.
197. Tian YM, Mole DR, Ratcliffe PJ, and Gleadle JM. Characterization of different isoforms of the HIF prolyl hy-droxylase PHD1 generated by alternative initiation. Biochem J 397: 179-186, 2006.
198. Vachal P, Miao S, Pierce JM, Guiadeen D, Colandrea VJ, Wyvratt MJ, Salowe SP, Sonatore LM, Milligan JA, Hajdu R, Gollapudi A, Keohane CA, Lingham RB, Mandala SM, DeMartino JA, Tong X, Wolff M, Steinhuebel D, Kieczy-kowski GR, Fleitz FJ, Chapman K, Athanasopoulos J, Adam G, Akyuz CD, Jena DK, Lusen JW, Meng J, Stein BD, Xia L, Sherer EC, and Hale JJ. 1, 3, 8-Triazaspiro[4.5]decane- 2, 4-diones as efficacious pan-inhibitors of hypoxia-induc-ible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia. J Med Chem 55: 2945-2959, 2012.
199. Vincent KA, Feron O, and Kelly RA. Harnessing the response to tissue hypoxia: HIF-1 alpha and therapeutic an-giogenesis. Trends Cardiovasc Med 12: 362-367, 2002.
200. Walmsley SR, Chilvers ER, Thompson AA, Vaughan K, Marriott HM, Parker LC, Shaw G, Parmar S, Schneider M, Sabroe I, Dockrell DH, Milo M, Taylor CT, Johnson RS, Pugh CW, Ratcliffe PJ, Maxwell PH, Carmeliet P, and Whyte MK. Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice. J Clin Invest 121: 1053-1063, 2011.
201. Wang F, Song X, Zhou M, Wei L, Dai Q, Li Z, Lu N, and Guo Q. Wogonin inhibits H2O2-induced vascular permeability through suppressing the phosphorylation of caveo-lin-1. Toxicology 305: 10-19, 2013.
202. 2 tension. Proc Natl Acad Sci U S A 92: 5510-5514, 1995.
203. Wang J, Chen G, Muckenthaler M, Galy B, Hentze MW, and Pantopoulos K. Iron-mediated degradation of IRP2, an unexpected pathway involving a 2-oxoglutarate-dependent oxygenase activity. Mol Cell Biol 24: 954-965, 2004.
204. Ward JP. Oxygen sensors in context. Biochim Biophys Acta 1777: 1-14, 2008.
205. Warnecke C, Griethe W, Weidemann A, Jurgensen JS, Willam C, Bachmann S, Ivashchenko Y, Wagner I, Frei U, Wiesener M, and Eckardt KU. Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J 17: 1186-1188, 2003.
206. Wenger RH. Mitochondria: oxygen sinks rather than sensors? Med Hypotheses 66: 380-383, 2006.
207. Wenger RH and Gassmann M. Oxygen(es) and the hyp-oxia-inducible factor-1. Biol Chem 378: 609-616, 1997.
208. Wenger RH, Stiehl DP, and Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005: re12, 2005.
209. Winter SC, Shah KA, Han C, Campo L, Turley H, Leek R, Corbridge RJ, Cox GJ, and Harris AL. The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 107: 757-766, 2006.
210. Wong BW, Kuchnio A, Bruning U, and Carmeliet P. Emerging novel functions of the oxygen-sensing prolyl hy-droxylase domain enzymes. Trends Biochem Sci 38: 3-11, 2013.
211. Wu XY, Fu ZX, Wang XH, and Shen W. Identification of differential proteins in colon cancer SW480 cells with HIF1-alpha silence by proteome analysis. Neoplasma 57: 299-305, 2010.
212. Xiao Q, Zeng S, Ling S, and Lv M. Up-regulation of HIF-1alpha and VEGF expression by elevated glucose concentration and hypoxia in cultured human retinal pigment epithelial cells. J Huazhong Univ Sci Technolog Med Sci 26: 463-465, 2006.
213. Yang J, Staples O, Thomas LW, Briston T, Robson M, Poon E, Simoes ML, El-Emir E, Buffa FM, Ahmed A, Annear NP, Shukla D, Pedley BR, Maxwell PH, Harris AL, and Ashcroft M. Human CHCHD4 mitochondrial proteins regulate cellular oxygen consumption rate and metabolism and provide a critical role in hypoxia signaling and tumor progression. J Clin Invest 122: 600-611, 2012.
214. Yoon D, Pastore YD, Divoky V, Liu E, Mlodnicka AE, Rainey K, Ponka P, Semenza GL, Schumacher A, and Prchal JT. Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development. J Biol Chem 281: 25703-25711, 2006.
215. Yu X, Fang Y, Liu H, Zhu J, Zou J, Xu X, Jiang S, and Ding X. The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration. Nephrol Dial Transplant 27: 3110-3119, 2012.
216. Zhang J and Li D. Effect of conjugated linoleic acid on inhibition of prolyl hydroxylase 1 in hearts of mice. Lipids Health Dis 11: 22, 2012.
217. Zhao HX, Wang XL, Wang YH, Wu Y, Li XY, Lv XP, Zhao ZQ, Zhao RR, and Liu HR. Attenuation of myocardial injury by postconditioning: role of hypoxia inducible factor-1alpha. Basic Res Cardiol 105: 109-118, 2010.
218. Zhou YF, Zheng XW, Zhang GH, Zong ZH, and Qi GX. The effect of hypoxia-inducible factor 1-alpha on hypoxia-induced apoptosis in primary neonatal rat ventricular myocytes. Cardiovasc J Afr 21: 37-41, 2010.